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OBJECTIVEdTo assess the association between circulating angiogenic and antiangiogenic
factors in the second trimester and risk of preeclampsia in women with type 1 diabetes.
RESEARCH DESIGN AND METHODSdMaternal plasma concentrations of placental
growth factor (PlGF), soluble fms-like tyrosine kinase 1 (sFlt-1), and soluble endoglin (sEng)
were available at 26 weeks of gestation in 540 women with type 1 diabetes enrolled in the
Diabetes and Preeclampsia Intervention Trial.
RESULTSdPreeclampsia developed in 17% of pregnancies (n = 94). At 26 weeks of gestation,
women in whom preeclampsia developed later had signiﬁcantly lower PlGF (median [interquartile
range]: 231 pg/mL [120–423] vs. 365 pg/mL [237–582]; P , 0.001), higher sFlt-1 (1,522 pg/mL
[1,108–3,393] vs. 1,193 pg/mL [844–1,630] P, 0.001), and higher sEng (6.2 ng/mL [4.9–7.9] vs.
5.1 ng/mL[(4.3–6.2]; P, 0.001) compared with women who did not have preeclampsia. In addi-
tion, the ratio of PlGF to sEng was signiﬁcantly lower (40 [17–71] vs. 71 [44–114]; P, 0.001) and
the ratio of sFlt-1 to PlGF was signiﬁcantly higher (6.3 [3.4–15.7] vs. 3.1 [1.8–5.8]; P, 0.001) in
women who later developed preeclampsia. The addition of the ratio of PlGF to sEng or the ratio of
sFlt-1 to PlGF to a logistic model containing established risk factors (area under the curve [AUC],
0.813) signiﬁcantly improved the predictive value (AUC, 0.850 and 0.846, respectively; P, 0.01)
and signiﬁcantly improved reclassiﬁcation according to the integrated discrimination improvement
index (IDI) (IDI scores 0.086 and 0.065, respectively; P, 0.001).
CONCLUSIONSdThese data suggest that angiogenic and antiangiogenic factors measured
during the second trimester are predictive of preeclampsia in women with type 1 diabetes. The
addition of the ratio of PlGF to sEng or the ratio of sFlt-1 to PlGF to established clinical risk factors
signiﬁcantly improves the prediction of preeclampsia in women with type 1 diabetes.
Diabetes Care 36:3671–3677, 2013
P reeclampsia is characterized by thedevelopment of hypertension andnew-onset proteinuria during the
second half of pregnancy (1,2), leading
to increased maternal morbidity and
mortality (3). Women with type 1 diabe-
tes are at increased risk for development
of preeclampsia during pregnancy, with
rates being two-times to four-times higher
than that of the background maternity
population (4,5). Small advances have
come from preventive measures, such as
low-dose aspirin in women at high risk
(6); however, delivery remains the only
effective intervention, and preeclampsia
is responsible for up to 15% of preterm
births and a consequent increase in infant
mortality and morbidity (7).
Although the etiology of preeclamp-
sia remains unclear, abnormal placental
vascular remodeling and placental ische-
mia, together with maternal endothelial
dysfunction, hemodynamic changes, and
renal pathology, contribute to its patho-
genesis (8). In addition, over the past de-
cade accumulating evidence has suggested
that an imbalance between angiogenic
factors, such as placental growth factor
(PlGF), and antiangiogenic factors, such as
soluble fms-like tyrosine kinase 1 (sFlt-1)
and soluble endoglin (sEng), plays a key
role in the pathogenesis of preeclampsia
(8,9). In women at low risk (10–13) and
women at high risk (14,15), concentrations
of angiogenic and antiangiogenic factors
are signiﬁcantly different between women
who later develop preeclampsia (lower
PlGF, higher sFlt-1, and higher sEng levels)
compared with women who do not.
Few studies have speciﬁcally focused
on circulating angiogenic factors and risk
of preeclampsia in women with diabetes,
and the results have been conﬂicting. In a
small study, higher sFlt-1 and lower PlGF
were reported at the time of delivery in
women with diabetes who developed
preeclampsia (16). In a longitudinal pro-
spective cohort of pregnant women with
diabetes, Yu et al. (17) reported increased
sFlt-1 and reduced PlGF in the early third
trimester as potential predictors of pre-
eclampsia in women with type 1 diabetes,
but they did not show any difference in
sEng levels in women with preeclampsia
compared with women without pre-
eclampsia. By contrast, Powers et al. (18)
reported only increased sEng in the second
trimester in women with pregestational di-
abetes who developed preeclampsia.
c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c
From the 1Centre for Public Health, School of Medicine, Dentistry, and Biomedical Sciences, Queen’s Uni-
versity Belfast, Belfast, United Kingdom; the 2Department of Obstetrics, St. Mary’s Hospital, Central
Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre,
Manchester, United Kingdom; the 3Department of Diabetes, Aberdeen Royal Inﬁrmary, Aberdeen, United
Kingdom; the 4Department of Diabetes, St. John’s Hospital at Howden,West Lothian, United Kingdom; and
the 5Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, United Kingdom.
Corresponding author: Valerie A. Holmes, v.holmes@qub.ac.uk.
Received 22 April 2013 and accepted 31 May 2013.
DOI: 10.2337/dc13-0944
© 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and thework is not altered. See http://creativecommons.org/
licenses/by-nc-nd/3.0/ for details.
care.diabetesjournals.org DIABETES CARE, VOLUME 36, NOVEMBER 2013 3671
P a t h o p h y s i o l o g y / C o m p l i c a t i o n s
O R I G I N A L A R T I C L E
The aim of this study, which was sig-
niﬁcantly larger than the previous studies
highlighted, was to assess the association
between circulating angiogenic (PlGF) and
antiangiogenic (sFlt-1 and sEng) factors
and the risk of preeclampsia in women
with type 1 diabetes. A further aim was to
evaluate the added predictive ability and
clinical usefulness of angiogenic factors
and established risk factors for preeclamp-
sia risk prediction in women with type 1
diabetes.
RESEARCH DESIGN AND
METHODSdThe study population
comprised a subset of women with type 1
diabetes who were recruited into the Di-
abetes and Preeclampsia Intervention Trial
(DAPIT) (19) from 25 joint antenatal–
metabolic clinics across Northern Ireland,
Scotland, and Northwest England be-
tween April 2003 and June 2008. DAPIT
was a multicenter, randomized, placebo-
controlled intervention trial of vitamin C
and vitamin E supplementation during
pregnancy to prevent preeclampsia in
women with type 1 diabetes. Eligibility cri-
teria included type 1 diabetes preceding
pregnancy, singleton pregnancy, and age
16 years or older. Women were enrolled
in the study between 8 and 22 weeks of
gestation, with a mean gestational age at
randomization of 14 weeks of gestation
(19). Written informed consent was ob-
tained from all women. TheWestMidlands
Multicentre Research Ethics Committee
provided ethical approval (MREC02/7/016).
Preeclampsiawas the primary outcome
in DAPIT and was deﬁned as gestational
hypertension with proteinuria for previ-
ously normotensive women according to
the International Society for the Study of
Hypertension in Pregnancy (ISSHP) guide-
lines (1) and according to the National
High Blood Pressure Education Program
Working Groups guidelines for women
with preexisting hypertension or protein-
uria (2), as previously described (19). Each
case of hypertensive pregnancy was con-
ﬁrmed by three senior clinicians acting
independently.
Study-speciﬁc peripheral venous
blood samples were collected from women
enrolled in DAPIT at 26 weeks of gestation
(62 weeks) and after separation were
stored immediately at 2708C until analy-
sis. Plasma samples were batch-analyzed
centrally and concurrently in the Nutrition
and Metabolism Laboratories, Centre for
Public Health, Queen’s University Belfast.
Commercially available immunoassay kits
from R&D Systems (Minneapolis, MN)
were used to measure circulating angio-
genic (PlGF) and antiangiogenic (sFlt-1
and sEng) factors. All kits for each analyte
were from the same manufacturing batch
and laboratory staff members performing
the analyses were blind to the pregnancy
outcome (preeclampsia or no preeclamp-
sia). Mean interassay coefﬁcients of varia-
tion were 8.3% for PlGF, 16.6% for sFlt-1,
and 8.6% for sEng.
The original DAPIT trial of vitamin C
and vitamin E for the prevention of pre-
eclampsia indicated that antioxidants did
not signiﬁcantly reduce risk of pre-
eclampsia in women with type 1 diabetes
(15% vs. 19%; risk ratio, 0.81; 95% CI,
0.59–1.12; P = 0.20) (19). There was no
signiﬁcant difference in the concentrations
of PlGF, sFlt-1, and sEng between the an-
tioxidant and placebo groups. In addition,
there was no signiﬁcant interaction be-
tween treatment group and the angiogenic
and antiangiogenic markers in the logistic
regression models for preeclampsia risk.
Therefore, the treatment group and placebo
group were combined for these analyses.
Statistical analysis
Analysis of sEng, sFlt-1, PlGF, ratio of PlGF
to sEng, and ratio of sFlt-1 to PlGF was
performed after logarithmic transformation
and values are reported as median (inter-
quartile range). Comparisons between
those who later developed preeclampsia
and those who did not were performed
using independent sample t tests and x2
tests. Logistic regression analysis was used
to assess the association of the angiogenic
and antiangiogenic factors with preeclamp-
sia and was adjusted for established risk
factors, including age, BMI, diabetes dura-
tion, parity, history of preeclampsia, current
smoking, and clinical parameters measured
at the time of blood sampling, such as
second trimester systolic blood pressure,
diastolic blood pressure, HbA1c, and renal
status (normoalbuminuria, microalbumi-
nuria, or macroalbuminuria). Analyses
also were adjusted for gestation at blood
sampling and treatment group assignment
in the original DAPIT trial.
To assess the performance of angio-
genic and antiangiogenic markers mea-
sured in the second trimester for the
prediction of preeclampsia in women with
type 1 diabetes, receiver operating charac-
teristic analysis was derived from the logistic
model, both with and without covariates.
In addition, to quantify the added clinical
value of these biomarkers in comparison
with established clinical risk factors, the
integrated discrimination improvement
Table 1dMaternal characteristics and second trimester clinical proﬁles in women with
and without preeclampsia
Preeclampsia,
n = 94
No preeclampsia,
n = 446 P
Age, years 29.9 (5.5) 30.1 (5.5) 0.74
Gestational age at second trimester visit 26.1 (1.6) 26.4 (1.5) 0.05
BMI
BMI, kg/m2† 27.7 (4.0) 27.6 (5.2) 0.87
Overweight or obese (BMI .25 kg/m2) 72 (79%) 280 (64%) 0.006
Primiparous 58 (62%) 196 (44%) 0.002
History of preeclampsia 18 (19%) 43 (10%) 0.008
Diabetes duration, years 16.1 (7.3) 14.1 (8.4) 0.04
Current smoker 12 (13%) 84 (19%) 0.16
Systolic BP at second trimester visit, mmHg‡ 126.4 (13.1) 118.4 (11.9) ,0.001
Diastolic BP at second trimester visit, mmHg‡ 80.6 (8.4) 74.3 (8.2) ,0.001
HbA1c at second trimester visit, %x 6.9 (0.9) 6.7 (0.8) 0.01
HbA1c at second trimester visit, mmol/molx 52 (10) 49 (9) 0.01
Renal status at second trimester visit|{ ,0.001
Normoalbuminuria 50 (60%) 349 (87%)
Microalbuminuria 15 (18%) 33 (8%)
Macroalbuminuria 18 (22%) 19 (5%)
Data are mean (SD) or n (%) unless otherwise stated. BP, blood pressure. †BMI calculated at a mean age of 14
weeks of gestation. Data available for 91 women with preeclampsia and 437 women without preeclampsia.
‡Data available for 93 women with preeclampsia and 445 women without preeclampsia. xData available for
91 women with preeclampsia and 431 women without preeclampsia. ||Data available for 83 women with
preeclampsia and 401 women without preeclampsia. {Ratio of urine albumin to creatinine (ACR): nor-
moalbuminuria, ACR ,3.5 mg/mmol; microalbuminuria, ACR $3.5 mg/mmol and ,30 mg/mmol; mac-
roalbuminuria, ACR $30 mg/mmol.
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index (IDI) and net reclassiﬁcation im-
provement index (NRI) were calculated
for each measure as described by Pencina
et al. (20). The NRI requires that pre-
eclampsia risks predicted by the logistic
model are assigned to categories. We used
the following three categories:,10%; 10–
19.9%; and$20%. The categorization ob-
tained from a logistic model containing
only established risk factors was compared
with the categorization obtained after add-
ing the angiogenic factor to the model. The
proportion of patients with preeclampsia
moved to a higher risk category (net of
any moved to a lower risk category) was
calculated. Likewise, the proportion of pa-
tients without preeclampsia moved to a
lower risk category (net of any moved
to a higher risk category) was calculated.
The sumof these twoproportions provided
the NRI. The IDI was calculated using the
predicted risks without the need for cate-
gorization and thereforewas not affected by
the choice of cutoff values for the catego-
ries. It was deﬁned as the average increase
in predicted risk among patients with pre-
eclampsia added to the average decrease in
predicted risk among patients without pre-
eclampsia. Established risk factors included
age, BMI, diabetes duration, parity, history
of preeclampsia, smoking status, and sec-
ond trimester clinical measures such as
systolic blood pressure, diastolic blood
pressure,HbA1c, and ratio of urine albumin
to creatinine. Analyses also were adjusted
for gestation at the time of blood sampling
and treatment group assignment in the
original DAPIT trial. Statistical analyses
were performed using SPSS version 17
(SPSS, Chicago, IL) and Stata release 11
(StataCorp, College Station, TX).
RESULTSdA total of 762 women were
enrolled in the Diabetes and Preeclampsia
Intervention Trial. Blood samples were
available for analysis of angiogenic and
antiangiogenic factors in the second tri-
mester for 540 women, of whom 94
women (17%) developed preeclampsia,
concordant with the overall rate of pre-
eclampsia in the full DAPIT cohort (19).
In addition, the preterm delivery rate of
37% in those subjects with available sam-
ples was in agreement with the overall rate
in the full DAPIT cohort. Of the women
delivering before 37 weeks of gestation,
31% had preeclampsia compared with
10% of those delivering after 37 weeks of
gestation.
Maternal characteristics and second
trimester clinical proﬁles for women with
and without preeclampsia are shown in
Table 1. Although there was no signiﬁcant
difference in BMI between the groups,
more womenwith preeclampsia were over-
weight or obese (BMI.25kg/m2).Women
with preeclampsia were more likely to be
primiparous, to have a history of pre-
eclampsia, and to have a longer duration
of diabetes. Women who developed pre-
eclampsia had signiﬁcantly higher second
trimester measurements of systolic blood
pressure, diastolic blood pressure, and
HbA1c concentrations, and they were more
likely to have microalbuminuria or macro-
albuminuria. Blood sampling was per-
formed slightly earlier in women who
later developed preeclampsia when com-
pared with those who did not (mean [SD]
gestational age 26.1 weeks [1.6] vs. 26.4
weeks [1.5]; P = 0.05).
Angiogenic and antiangiogenic mark-
ers measured during the second trimester
were signiﬁcantly different in women with
subsequent development of preeclampsia
compared with those who did not develop
preeclampsia (Table 2). At 26weeks of ges-
tation, women who later developed pre-
eclampsia had signiﬁcantly lower PlGF,
signiﬁcantly higher sFlt-1, and signiﬁcantly
higher sEng compared with women who
did not develop preeclampsia. In addition,
the ratio of PlGF to sEng was signiﬁcantly
lower and the ratio of sFlt-1 to PlGF was
signiﬁcantly higher inwomenwho later de-
veloped preeclampsia. A similar pattern of
angiogenic and antiangiogenic factors was
evident in women who delivered before
and after 37 weeks of gestation, with the
exception of sEng, which was more com-
parable in women with and without pre-
eclampsia who delivered at term (after 37
weeks of gestation) (Table 2).
To further explore the role of angio-
genic and antiangiogenic factors, the risk
of preeclampsia was examined in relation
to quarters of the distribution of each
biomarker, both unadjusted and adjusted
for established risk factors (Table 3). After
adjustment, a signiﬁcant association re-
mained between the three higher risk quar-
ters and the reference lowest risk quarter
for sFlt-1. For sEng, PlGF, ratio of PlGF
to sEng, and ratio of sFlt-1 to PlGF, a sig-
niﬁcant association was evident between
the two highest risk quarters compared
with the reference lowest risk quarter.
Receiver operating characteristic anal-
ysis of angiogenic and antiangiogenic fac-
tors was used to assess the predictive value
of angiogenic factor and clinical factor mea-
sures for preeclampsia (Table 4). The area
Table 2dAngiogenic and antiangiogenic factors at 26 weeks of gestation in women with
type 1 diabetes with subsequent development of preeclampsia
All women (n = 540)
Preeclampsia
(n = 94)
No preeclampsia
(n = 446) P
sEng, ng/mL 6.2 (4.9–7.9) 5.1 (4.3–6.2) ,0.001
sFlt-1, pg/mL 1,522 (1,108–3,393) 1,193 (844–1,630) ,0.001
PlGF, pg/mL 231 (120–423) 365 (237–582) ,0.001
PlGF:sEng ratio 40 (17–71) 71 (44–114) ,0.001
sFlt-1:PlGF ratio 6.3 (3.4–15.7) 3.1 (1.8–5.8) ,0.001
Delivered at ,37 weeks of
gestation (n = 198) Preeclampsia (n = 61) No preeclampsia (n = 137) P
sEng, ng/mL 6.4 (5.3–8.5) 5.3 (4.5–6.8) ,0.001
sFlt-1, pg/mL 1,583 (1,126–4,260) 1,235 (911–1,698) ,0.001
PlGF, pg/mL 221 (113–465) 371 (227–650) ,0.001
PlGF:sEng ratio 36 (15–69) 70 (39–130) ,0.001
sFlt-1:PlGF ratio 7.1 (3.5–17.6) 3.1 (1.7–7.7) ,0.001
Delivered at $37 weeks
of gestation (n = 342) Preeclampsia (n = 33) No preeclampsia (n = 309) P
sEng, ng/mL 5.5 (4.3–6.8) 5.0 (4.2–6.1) 0.07
sFlt-1, pg/mL 1,503 (1,050–1,826) 1,183 (818–1,583) 0.02
PlGF, pg/mL 253 (178–369) 364 (240–559) ,0.001
PlGF:sEng ratio 48 (25–83) 72 (47–110) ,0.001
sFlt-1:PlGF ratio 5.8 (3.4 – 8.6) 3.1 (1.9–5.5) ,0.001
Data presented as median (interquartile range).
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under the curve (AUC) ranged from 0.652
to 0.711. When established risk factors for
preeclampsia were entered into the logistic
model, the AUC increased for each mea-
sure, ranging from 0.826 to 0.850. The ad-
dition of PlGF, ratio of PlGF to sEng, or
ratio of sFlt-1 to PlGF to the logistic model
containing only established risk factors
(AUC, 0.813) signiﬁcantly improved the
predictive value (respectively: AUC, 0.838
[P = 0.04]; AUC, 0.850 [P = 0.008]; and
AUC, 0.846 [P = 0.008]).
Finally, the addition of any of the
angiogenic and antiangiogenic factors and
both angiogenic and antiangiogenic ratios
improved the ability of established risk
factors to predict preeclampsia using the
IDI (Table 4). Using the NRI, although
PlGF and PlGF-to-sEng ratio improved
the ability of established risk factors to pre-
dict risk of preeclampsia, this was not sta-
tistically signiﬁcant (P = 0.08 and P = 0.07,
respectively). The improvement in predicted
risk of preeclampsia (as measured by the
IDI) and in the reclassiﬁcation of pre-
eclampsia risk (as measured by the NRI)
for the DAPIT cohort for PlGF-to-sEng ra-
tio are shown in Fig. 1.
CONCLUSIONSdThis is the largest
study to date that has examined the role of
angiogenic and antiangiogenic factors in
the prediction of preeclampsia among
pregnant women with type 1 diabetes.
We observed higher sFlt-1, higher sEng,
lower PlGF, and signiﬁcantly altered an-
giogenic and antiangiogenic ratios during
the second trimester in women who later
developed preeclampsia compared with
those who did not. Furthermore, we have
shown for the ﬁrst time that the addition
of angiogenic and antiangiogenic markers,
particularly PlGF, ratio of PlGF to sEng,
and ratio of sFlt-1 to PlGF, to established
clinical risk factors improves the prediction
of preeclampsia within this population.
Our ﬁndings build on previously pub-
lished data within the DAPIT cohort in
relation to glycemic control and risk of
preeclampsia (21) and suggest that it may
be feasible, in the future, to devise a risk
assessment model for preeclampsia in
women with type 1 diabetes.
Concordant with other studies of the
general obstetric population involving
women at low risk (10–13) and women
at high risk (14,15), we found signiﬁ-
cantly different concentrations of angio-
genic and antiangiogenic markers in
women with type 1 diabetes who later de-
veloped preeclampsia (lower PlGF, higher
sFlt-1, and higher sEng levels) compared
with those who did not. Previous reports
of angiogenic markers for the prediction
of preeclampsia in women with diabetes
have been conﬂicting (17,18) and incon-
sistent compared those using general ob-
stetric populations (10–15). Powers et al.
(18) reported signiﬁcantly higher sEng at
26–30 weeks of gestation but no difference
in PlGF or sFlt-1. However, Yu et al. (17)
reported a signiﬁcant decrease in PlGF and a
signiﬁcant increase in sFlt-1 at 32 weeks of
gestation but no difference in sEng in
women with diabetes who later developed
preeclampsia compared with those who
did not. It is unclear why these results
(17,18) differ from those of DAPIT; how-
ever, it may be that numbers in these stud-
ies were too small to detect signiﬁcant
differences compared with the much larger
DAPIT cohort. Furthermore, there are sub-
tle differences in subject characteristics in
these other studies that may affect bio-
marker status. For example, whereas
women in the study by Yu et al. (17) had
type1diabetes, thosewithmicroalbuminuria
or other complications at baseline were
excluded. In the other study (18), women
were reported to have pregestational
insulin-treated diabetes and, as such,
may have included women with both type
1 and type 2 diabetes, between whom the
pathogenesis of preeclampsia may differ. In
our study, women who developed pre-
eclampsia, irrespective of gestational age at
delivery, had signiﬁcantly higher sEng at 26
weeks of gestation compared with women
who did not. Although sEng was signiﬁ-
cantly higher only in those women with
preeclampsia who delivered before 37
weeks of gestation, a similar trend was ob-
served in women delivering with pre-
eclampsia after 37 weeks of gestation,
although this did not reach statistical signif-
icance (P = 0.07).
Table 3dOdds ratios for preeclampsia according to quarter for sEng, sFlt-1, PlGF, PlGF:
sEng ratio, and sFlt-1:PlGF ratio
Quarter n Preeclampsia
Unadjusted
odds ratio
(95% CI)
Adjusted
odds ratio*
(95% CI)
P trend
unadjusted/
adjusted
sEng concentration,
ng/mL
,0.001/,0.001
Q1: #4.37 134 12 (9%) 1.0 (reference) 1.0 (reference)
Q2: 4.38–5.24 136 18 (13%) 1.6 (0.7–3.7) 1.9 (0.8–4.5)
Q3: 5.25–6.54 135 26 (19%) 2.4 (1.1–5.5) 2.6 (1.1–6.1)
Q4: $6.55 135 38 (28%) 4.0 (1.9–8.8) 5.7 (2.4–13.3)
sFlt-1 concentration,
pg/mL
,0.001/0.02
Q1: #873 135 9 (7%) 1.0 (reference) 1.0 (reference)
Q2: 874–1,232 135 25 (19%) 3.2 (1.4–8.1) 2.5 (1.1–5.9)
Q3: 1,233–1,688 135 23 (17%) 2.9 (1.2–7.3) 2.3 (1.0–5.6)
Q4: $1,689 135 37 (27%) 5.3 (2.4–13.0) 3.3 (1.4–7.9)
PlGF concentration,
pg/mL
,0.001/0.001
Q1: ,220 135 39 (29%) 3.8 (1.9–8.2) 3.7 (1.6–8.1)
Q2: 220–346 135 25 (19%) 2.1 (1.0–4.8) 2.4 (1.1–5.3)
Q3: 347–546 135 17 (13%) 1.4 (0.6–3.2) 1.3 (0.5–3.1)
Q4: $547 135 13 (10%) 1.0 (reference) 1.0 (reference)
PlGF:sEng ratio ,0.001/,0.001
Q1: #39.1 135 43 (32%) 5.8 (2.7–13.7) 7.3 (3.0–17.6)
Q2: 39.2–65.2 135 24 (18%) 2.7 (1.2–6.6) 3.7 (1.5–9.3)
Q3: 65.3–108.0 135 17 (13%) 1.8 (0.7–4.6) 2.2 (0.8–5.5)
Q4: $108.1 135 10 (7%) 1.0 (reference) 1.0 (reference)
sFlt-1:PlGF ratio ,0.001/,0.001
Q1: #2.00 135 8 (6%) 1.0 (reference) 1.0 (reference)
Q2: 2.01–3.50 135 17 (13%) 2.3 (0.9–6.3) 2.1 (0.8–5.6)
Q3: 3.51–6.55 135 27 (20%) 4.0 (1.7–10.5) 3.8 (1.5–9.5)
Q4: $6.56 135 42 (31%) 7.2 (3.1–18.4) 5.9 (2.4–14.6)
Q, quarter. *Adjusted for age, treatment group, gestation, BMI, diabetes duration, parity, history of pre-
eclampsia, current smoking, systolic blood pressure, diastolic blood pressure, HbA1c, and ratio of urine al-
bumin to creatinine at second trimester visit.
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Previous studies have reported the pre-
dictive performance of the sFlt-1-to-PlGF
ratio for early-onset preeclampsia in a het-
erogeneous group of high-risk pregnancies
(15) and among women with chronic hy-
pertension (22). The PlGF-1-to-sEng ratio
in the second trimester also was recently
reported as a novel and promising diagnos-
tic tool for prediction of early-onset pre-
eclampsia in singleton pregnancies (23),
although numbers were small. In the cur-
rent study,wehave been able to extrapolate
these ﬁndings to a well-characterized pop-
ulation ofwomenwith type 1 diabetes. Our
ﬁndings also demonstrate that in women
with type 1 diabetes, ratios have better di-
agnostic accuracy than any of the individ-
ual factors alone. In the current study, the
predictive AUC values for angiogenic and
antiangiogenic factors among all women in
the DAPIT cohort are similar to those re-
ported in high-risk pregnancies in which
preeclampsia developed at less than 37
weeks of gestation (14).
In clinical practice, traditional factors
such as age, BMI, diabetes duration, parity,
history of preeclampsia, blood pressure,
HbA1c, and ratio of urine albumin to creat-
inine are often considered to identify
women with diabetes at high risk for de-
velopment of preeclampsia, although no
speciﬁc preeclampsia risk function is yet
available. In our DAPIT cohort, the AUC
was 0.813 for these established risk factors,
endorsing their clinical utility and the im-
portance of careful monitoring of women
with diabetes throughout pregnancy. Per-
haps most importantly, we observed that
measures of angiogenic and antiangiogenic
activity (PlGF, ratio of PlGF to sEng, and
ratio of sFlt-1 to PlGF) signiﬁcantly im-
proved the AUC above and beyond tradi-
tional risk factors. Clinically, the question is
whether any of these potential biomarkers,
when added to current established risk fac-
tors, will offer a better estimate of an indi-
vidual woman’s risk, thus leading to more
effective monitoring, early intervention,
and possible selection of subjects for future
clinical trials. In the current study, the IDI
andNRI were used to examine whether the
addition of the biomarker of interest to
established risk factors would reclassify
individuals into higher and lower risk cat-
egories for future preeclampsia (20). Each
of the angiogenic and antiangiogenic fac-
tors and their ratios signiﬁcantly improved
discrimination as measured by the IDI,
whereas PlGF and PlGF-to-sEng ratio im-
proved overall reclassiﬁcation of women
into the correct risk category, albeit not
signiﬁcantly. However, in the absence of
established risk thresholds for treatment
of preeclampsia, the NRI categorization is
arbitrary and, thus, the IDI is considered
the more relevant index. Whereas these
data suggest that PlGF, ratio of PlGF to
sEng, and ratio of sFlt-1 to PlGF may be
useful biomarkers of future preeclampsia
risk in women with type 1 diabetes, this
needs to be validated in another prospec-
tive cohort (24).
The DAPIT study population is one of
the largest contemporary prospective da-
tasets of womenwith type 1 diabetes (19),
comprising a carefully characterized pop-
ulation of women with type 1 diabetes. A
major strength of this study is the extent
to which the ISSHP deﬁnition of pre-
eclampsia criteria has been applied, with
each hypertensive pregnancy being rigor-
ously reviewed and each diagnosis of pre-
eclampsia being conﬁrmed by three
senior clinicians. Another strength of the
study is the inclusion of all women with
type 1 diabetes, including those with es-
sential hypertension, microalbuminuria,
or macroalbuminuria. This allows us to
extrapolate the ﬁndings to the majority
of women with type 1 diabetes attending
for joint antenatal–metabolic care.
Nevertheless, our studyhas a number of
limitations. Although the inclusion criteria,
as noted, were intended to facilitate recruit-
ment, the subjects were a self-selecting
population who agreed to participate and,
thus, may not be totally representative of
the entire population ofwomenwith type 1
diabetes. Because the DAPIT intervention
of vitamin C and vitamin E did not signif-
icantly reduce the incidence of preeclamp-
sia, both treatment groups were combined
for analysis, albeit with adjustment for
treatment group in the logistic regression
model. The study only analyzed and re-
ported angiogenic and antiangiogenic fac-
tors measured at one time-point during
pregnancy, late in the second trimester.
Longitudinal measurement of angiogenic
factors would allow analysis of serial
changes during pregnancy and may signif-
icantly add to the predictive values of some
of these biomarkers. Likewise, uterine ar-
tery Doppler measurements were not avail-
able for these women and inclusion of such
studies would beneﬁt future exploration
and validation of a clinically useful pre-
dictive model. Finally, it was not possible
to date the onset of preeclampsia accu-
rately; therefore, the data were analyzed
by subgroups of women with preeclamp-
sia according to gestational age at delivery.
Nonetheless, regardless of gestational age
when preeclampsia was diagnosed, we
have demonstrated the clinical usefulness
of PlGF, ratio of PlGF to sEng, and ratio of
sFlt-1 to PlGF in the entire DAPIT cohort
and not just in those who delivered at early
gestation ages, as observed in other studies
(15,22,23).
Analysis of this large cohort of women
with type 1 diabetes conﬁrms that those
at risk for preeclampsia have lower PlGF,
higher sFlt-1, and higher sEng levels
during the second trimester as previously
observed in women at low risk (10–13)
and women at high risk (14,15). Further-
more, this study would suggest that these
markers may have additional predictive
risk above and beyond traditional clinical
risk factors. Validation of the potential use-
fulness of PlGF, ratio of PlGF to sEng, and
Table 4dAreas under the ROC curve, IDI, and NRI for logarithmically transformed
angiogenic and antiangiogenic variables in a logistic regression analysis with other
established risk factors*
Area under the
ROC curve without
covariates
Area under the
ROC curve with
covariates in
logistic model IDI NRI
AUC AUCl (P†) Score (P) Score (P)
sEng 0.665 0.839 (0.07) 0.071 (,0.001) 0.048 (0.36)
sFlt-1 0.652 0.826 (0.13) 0.025 (0.007) 20.003 (0.95)
PlGF 0.675 0.838 (0.04) 0.057 (,0.001) 0.103 (0.08)
PlGF:sEng ratio 0.703 0.850 (0.008) 0.086 (,0.001) 0.103 (0.07)
sFlt-1:PlGF ratio 0.711 0.846 (0.008) 0.065 (,0.001) 0.072 (0.20)
ROC, receiver operating characteristic; IDI, integrated discrimination improvement; NRI, net reclassiﬁcation
improvement. *Established risk factors (covariates) were age, BMI, diabetes duration, parity, history of
preeclampsia, smoking status, and second trimester clinical measures such as systolic blood pressure, di-
astolic blood pressure, HbA1c, and ratio of urine albumin to creatinine. Covariates also included treatment
group and gestation. †Relative to AUC of 0.813 for a logistic model containing only the covariates.
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ratio of sFlt-1 to PlGF in other diabetes co-
horts is now indicated with the aim of
deriving a predictive risk score for women
at risk for preeclampsia.
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